Apellis Pharmaceuticals Inc (APLS)
29.34
+1.36
(+4.86%)
USD |
NASDAQ |
Nov 04, 13:14
Apellis Pharmaceuticals Debt to Equity Ratio: 1.730 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.730 |
| March 31, 2024 | 0.3491 |
| December 31, 2023 | 0.4783 |
| September 30, 2023 | 0.4002 |
| June 30, 2023 | 0.2689 |
| March 31, 2023 | 0.2252 |
| December 31, 2022 | 0.5459 |
| September 30, 2022 | 0.3014 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.5661 |
| March 31, 2022 | 0.4092 |
| December 31, 2021 | 0.9515 |
| September 30, 2021 | -3.308 |
| June 30, 2021 | -2.731 |
| March 31, 2021 | 7.475 |
| December 31, 2020 | 1.754 |
| September 30, 2020 | 3.342 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-3.308
Minimum
Sep 2021
7.475
Maximum
Mar 2021
0.7974
Average
0.4437
Median
Debt to Equity Ratio Benchmarks
| Biomarin Pharmaceutical Inc | 0.1098 |
| Ionis Pharmaceuticals Inc | 4.842 |
| EyePoint Pharmaceuticals Inc | 0.00 |
| Cassava Sciences Inc | -- |
| Macrogenics Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 904.48M |
| Total Liabilities (Quarterly) | 640.16M |
| Shareholders Equity (Quarterly) | 264.33M |
| Current Ratio | 5.084 |
| Net Debt Paydown Yield | -1.56% |